1315 Capital raises $300m

The US-based expansion and growth equity firm closes second fund at hard-cap.

1315 Capital II has held a first and final close at its hard-cap of $300 million. The fund, which had initially targeted $250 million, will continue to pursue the firm’s core sectors: pharmaceuticals, medical technology, and healthcare companies based in the United States, investing between $10 million and $30 million per transaction.

The firm’s debut fund, 1315 Capital, previously closed at $203.44 million in July 2016.